Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Synta Initiates Phase II GIST Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Synta Initiates Phase II GIST Trial

Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

“We and our collaborators have been encouraged by the strong preclinical results for STA-9090 in GIST as well as early results from our solid tumor Phase I trials, where STA-9090 has generated objective tumor responses and has been well-tolerated, with the most common adverse events, fatigue and gastrointestinal toxicities, being manageable and reversible,” said Vojo Vukovic, M.D., Ph.D., senior vice president and chief medical officer, Synta Pharmaceuticals. “A particularly encouraging observation was that a GIST patient on our once-weekly dosing Phase I solid tumor study, who experienced disease progression while on multiple prior therapies, including Gleevec and Sutent, experienced substantial tumor shrinkage and stabilization of disease following treatment with STA-9090. We are looking forward to working closely with leading GIST investigators to evaluate the potential of STA-9090 to benefit patients with this disease.”

Synta expects to report data from the ongoing Phase I and Phase 1/2 trials and initiate studies in other cancer indications in 1H10.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters